Blueprint
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2019.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation of registrant’s name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x
] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule
101(b)(1):
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule
101(b)(7):
Note: Regulation S-T Rule
101(b)(7) only permits the submission in paper of a Form 6-K if
submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws
of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home
country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the
report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security
holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on
EDGAR.
This Report of Foreign Private Issuer on Form 6-K and the attached
exhibits 23.1, 99.1, 99.2 and
101 shall be incorporated by reference into the Company’s
effective Registration Statements on Form F-3, as amended and
supplemented (Registration Statement Nos. 333-172796 and
333-218297), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
Intellipharmaceutics International Inc.
|
|
|
(Registrant)
|
|
Date:
February 22, 2019
|
/s/ Greg Powell
|
|
|
Greg
Powell
|
|
|
Chief Financial Officer
|
EXHIBIT LIST
Consent of
Independent Registered Public Accounting Firm (MNP
LLP)
Management
Discussion and Analysis of Financial Condition and Results of
Operations for the Year Ended November 30, 2018
Consolidated
Financial Statements and Notes to Consolidated Financial Statements
of Intellipharmaceutics International Inc. for the Year Ended
November 30, 2018
News Release dated
February 22, 2019 - Intellipharmaceutics Announces 2018 Year End
Results
101
XBRL
(Extensible Business Reporting Language). The following materials
from Intellipharmaceutics International Inc.’s Consolidated
Financial Statements and Notes to the Consolidated Financial
Statements for the fiscal year-ended November 30, 2018, formatted
in XBRL:
(i)
Consolidated
balance sheets as at November 30, 2018 and 2017
(ii)
Consolidated
statements of operations and comprehensive loss for the years ended
November 30, 2018, 2017 and 2016
(iii)
Consolidated
statements of shareholders’ equity (deficiency) for the years
ended November 30, 2018, 2017 and 2016
(iv)
Consolidated
statements of cash flows for the years ended November 30, 2018,
2017 and 2016
(v)
Notes
to the consolidated financial statements